MannKind Corp. pledged Monday to continue developing its insulin inhaler system even though its stock fell after Eli Lilly & Co. said last week that it had given up on a similar diabetes treatment. The Valencia biotech firm’s president said MannKind stock, which has lost more than two-thirds of its value in the last year, would bounce back once investors realized its product was superior to the one Lilly had been pursuing. For the full story visit
